NASDAQ:CFRXContraFect Stock Price, Forecast & News

ContraFect's stock was trading at $6.96 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CFRX shares have decreased by 26.1% and is now trading at $5.14. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ContraFect in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for ContraFect.

ContraFect is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for ContraFect.

ContraFect Corp (NASDAQ:CFRX) announced its earnings results on Friday, May, 15th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.10. View ContraFect's earnings history.

ContraFect shares reverse split before market open on Tuesday, February 4th 2020. The 1-10 reverse split was announced on Tuesday, February 4th 2020. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 3rd 2020. An investor that had 100 shares of ContraFect stock prior to the reverse split would have 10 shares after the split.

2 Wall Street analysts have issued 12 month price targets for ContraFect's shares. Their forecasts range from $15.00 to $22.00. On average, they anticipate ContraFect's share price to reach $18.50 in the next twelve months. This suggests a possible upside of 259.9% from the stock's current price. View analysts' price targets for ContraFect.

Media headlines about CFRX stock have been trending positive recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. ContraFect earned a coverage optimism score of 2.8 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news aboutContraFect.

ContraFect saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 736,500 shares, an increase of 25.2% from the April 30th total of 588,200 shares. Based on an average daily trading volume, of 182,100 shares, the days-to-cover ratio is presently 4.0 days. Approximately 6.1% of the shares of the stock are short sold. View ContraFect's Current Options Chain.

Some companies that are related to ContraFect include MannKind (MNKD), Verastem (VSTM), Lannett (LCI), Avadel Pharmaceuticals (AVDL), Neptune Wellness Solutions (NEPT), AMAG Pharmaceuticals (AMAG), Menlo Therapeutics (MNLO), Concert Pharmaceuticals (CNCE), CymaBay Therapeutics (CBAY), Chiasma (CHMA), ProQR Therapeutics (PRQR), Hookipa Pharma (HOOK), Spero Therapeutics (SPRO), Affimed (AFMD) and Agile Therapeutics (AGRX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other ContraFect investors own include Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Verastem (VSTM), Novavax (NVAX), Gilead Sciences (GILD), Cidara Therapeutics (CDTX), Matinas BioPharma (MTNB), VBI Vaccines (VBIV), Vaxart (VXRT) and Crispr Therapeutics (CRSP).

ContraFect trades on the NASDAQ under the ticker symbol "CFRX."

ContraFect's stock is owned by a variety of retail and institutional investors. Top institutional investors include Federated Hermes Inc. (19.89%), Fosun International Ltd (4.86%), White Pine Capital LLC (0.96%), Oracle Investment Management Inc. (0.84%), Geode Capital Management LLC (0.68%) and Minot Wealth Management LLC (0.45%). Company insiders that own ContraFect stock include Cary Sucoff, Fosun Pharmaceutical Shanghai and Michael Messinger. View institutional ownership trends for ContraFect.

CFRX stock was sold by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Fosun International Ltd, Oracle Investment Management Inc., White Pine Capital LLC, Minot Wealth Management LLC, Geode Capital Management LLC, and BlackRock Inc.. View insider buying and selling activity for ContraFect.

CFRX stock was purchased by a variety of institutional investors in the last quarter, including Morgan Stanley, Squarepoint Ops LLC, Spark Investment Management LLC, and Jane Street Group LLC. Company insiders that have bought ContraFect stock in the last two years include Cary Sucoff, and Michael Messinger. View insider buying and selling activity for ContraFect.

Shares of CFRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CFRX stock can currently be purchased for approximately $5.14.

ContraFect has a market capitalization of $78.81 million. The biotechnology company earns $-12,790,000.00 in net income (profit) each year or $1.11 on an earnings per share basis. ContraFect employs 20 workers across the globe.

The official website for ContraFect is www.contrafect.com.

ContraFect's mailing address is 28 WELLS AVENUE 3RD FLOOR, YONKERS NY, 10701. The biotechnology company can be reached via phone at 914-207-2300 or via email at [email protected]